NoVir
Novel Virus-agnostic Broad Spectrum Antiviral mRNA for Pandemic
- Description
The COVID-19 pandemic highlighted the limitations of existing measures in addressing widespread viral outbreaks. The absence of a rapid-response, broad-spectrum antiviral—capable of targeting multiple viruses—contributed to significant health and societal impacts.
Funded by the EU4Health Programme, established in response to the COVID-19 pandemic to strengthen Europe’s healthcare systems and improve preparedness for future health crises, the NoVir project supports several preclinical and clinical studies to evaluate the potential of ETH47, a first-in-class mRNA-based antiviral therapy. ETH47’s ability to act at virus entry sites, combined with its room-temperature stability and potential synergy with existing antivirals, positions it as a differentiated and scalable solution for pandemic preparedness. One of the major objectives of the NoVir team is to advance ETH47’s clinical development and explore its wider applications beyond respiratory conditions, to address additional critical unmet needs in high-risk populations.
- Coordinator
- Dr Carsten RudolphEthris GmbH, Germany
- Disclaimer
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.
- Programme
- Other
- Duration
- 24 months (May 2025 - April 2027)
- Project funding
- € 9,977,918.00
- Project partners
- 4
- Technology readiness level
- 6
